Introduction
============

Pituitary adenomas, accounting for \~15% of all diagnosed intracranial tumors, are benign monoclonal adenomas that originate from cells of the anterior pituitary gland ([@b1-ol-0-0-3904]). Surgical resection, with or without adjuvant radiotherapy, is always the first line of treatment for the majority of pituitary adenomas, with the exception of prolactinomas ([@b2-ol-0-0-3904]). However, these treatments cannot usually control invasive pituitary adenomas due to the limited understanding of the underlying molecular mechanisms. Thereby, further research into the tumorigenesis will contribute to identifying novel therapeutic targets, which will be conductive to the development of novel therapeutic approaches for pituitary adenomas.

In past years, considerable progress has been made in identifying the key players in pituitary adenomas. A previous study has shown that the phosphoinositide 3-kinase/AKT signaling pathway is activated and enhanced in pituitary adenomas, which may be due to the mutation and amplification of an oncogene, *PIK3CA* ([@b3-ol-0-0-3904]). Mutation in another oncogene, *GNAS*, which encodes the guanine nucleotide-activating α subunit has also been suggested to be involved in pituitary hyperplasia ([@b4-ol-0-0-3904]). Meanwhile, a tumor suppressor aryl hydrocarbon receptor-interacting protein has been demonstrated to function in modulating cellular signaling and cAMP signaling pathways via regulation of the localization of the aryl hydrocarbon receptor ([@b5-ol-0-0-3904]). Also, the absence of expression of another two tumor suppressors, growth arrest and DNA-damage-inducible β (GADD45β) and γ (GADD45γ), has been observed in human pituitary adenomas ([@b6-ol-0-0-3904],[@b7-ol-0-0-3904]). Aberrant methylation of a number of genes, such as *DAPK* ([@b8-ol-0-0-3904]) and *FGFR2* ([@b9-ol-0-0-3904]) has been confirmed to have a momentous role in pituitary tumorigenesis. Additionally, certain cell cycle regulators, such as p16, p21, p27, cyclin D1 and cyclin E, have also been demonstrated to function in pituitary tumorigenesis ([@b8-ol-0-0-3904],[@b10-ol-0-0-3904]). Recently, certain microRNAs (miRNA/miR) have been found to be crucial in pituitary adenomas. For instance, the expression levels of miR-431 and miR-770-5p have been found to be slightly higher in non-functioning pituitary adenomas compared to their levels in the normal pituitary gland ([@b11-ol-0-0-3904]). Recently, another study has shown that miRNA-dependent impairment of the HMGA/E2F1 pathway functions as pro-oncogene signaling in pituitary adenomas. Several miRNAs targeting *HMGA2* (miR-326, miR-570 and miR-432) or *E2F1* (miR-326 and miR-603) could inhibit the growth of pituitary cell lines (HP75 and GH3) ([@b12-ol-0-0-3904]).

Lee *et al* demonstrated that gonadotroph adenomas in MENX-affected rats closely resemble their human counterparts ([@b13-ol-0-0-3904]). The study further found that *CYP11A1* and *NUSAP1*, two commonly dysregulated differentially-expressed genes (DEGs) in the gonadotroph adenomas of rats and humans, are upregulated in 77 and 95% of human gonadotroph adenomas, respectively. Using the microarray data deposited by Lee *et al*, the present study aimed to further identify genes that were differentially expressed between pituitary adenomas samples and normal controls. Following Gene Ontology (GO) functional and pathway enrichment analysis of the screened DEGs, Protein-Protein Interaction (PPI) networks were constructed for the up- and downregulated DEGs, respectively, in order to learn more about the interaction of proteins encoded by DEGs, which may aid in our understanding of the molecular mechanisms of pituitary adenomas. The results are expected to assist in elucidating the etiology of pituitary adenomas, and provide novel insights for the clinical diagnosis of this disease.

Materials and methods
=====================

### Affymetrix microarray data

The gene expression profile data of GSE23207 ([@b13-ol-0-0-3904]) were acquired from Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>), which was based on the platform of the GPL6247 \[RaGene-1_0-st\] Affymetrix Rat Gene 1.0 ST Array. This dataset contains 16 samples of pituitary homozygous mutants (p27Kip1/Cdknb1) from MENX-associated rats, aged 7--8 months, with large tumors 1--2 mm in size, and 5 samples of normal pituitary tissues purchased from BioChain Inc. (Hayward, CA, USA).

### Data preprocessing and screening of DEGs

CEL files and probe annotation files were downloaded, and the gene expression data of all the samples were preprocessed via the Robust Multichip Averaging background correction ([@b14-ol-0-0-3904]), quantile normalization and probe summarization methods using the Oligo package ([@b15-ol-0-0-3904]). The Linear Models for Microarray Data package ([@b16-ol-0-0-3904]) of R was used for the identification of genes that were significantly differentially expressed in pituitary adenomas samples. The raw P-value was adjusted by the Benjamin and Hochberg method ([@b17-ol-0-0-3904]), and only the genes meeting the cut-off criteria of a \|log~2~fold change (FC)\| of \>1 and an adjusted P-value of \<0.05 were selected as DEGs.

### GO and pathway enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery (DAVID) gene functional classification tool now provides a comprehensive set of novel and powerful tools for researchers to understand the biological meaning behind abundant genes ([@b18-ol-0-0-3904]). Pathway enrichment analysis was conducted to identify the significant metabolic pathways for the DEGs ([@b19-ol-0-0-3904]). P\<0.05 and a count number of \>2 were used as the cut-off criteria for GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses by DAVID.

### PPI network construction

The Search Tool for the Retrieval of Interacting Genes database was used to analyze the PPIs for DEGs by calculating the combined scores ([@b20-ol-0-0-3904]), and a score \>0.4 was chosen as the cut-off. Next, PPI networks for up- and downregulated DEGs were visualized using Cytoscape (<http://cytoscape.org/>) ([@b21-ol-0-0-3904]). The highly connected nodes (hub proteins) were detected by calculating the degree of each node protein based on the scale-free property of interaction networks ([@b22-ol-0-0-3904]).

Results
=======

### Identification of DEGs

Based on the cut-off criteria, a total of 629 DEGs were screened from the pituitary adenomas samples, including 391 upregulated and 238 downregulated DEGs.

### Enrichment analysis of up- and downregulated DEGs

According to GO functional annotation, the upregulated DEGs were mainly enriched in GO terms associated with the cell cycle and cell division. For example, DEGs such as *CCNA2*, *NUSAP1*, *CCNB1*, *CENPF*, *CDC20* and *SPC25* were significantly involved in the cell cycle (P=1.08×10^−12^); *NUSAP1*, *CENPF*, *SPC25*, *CDC20* and *CCNB1* were involved in the M phase (P=3.09×10^−11^); and DEGs such as *CCNB1*, *SPC25*, *TOP2A*, *CDC20* and *CCNA2* were correlated with cell division (P=1.25×10^−7^). Notably, *PTTG1* was found to be enriched in every GO term ([Table I](#tI-ol-0-0-3904){ref-type="table"}). The downregulated DEGs, such as *KCND3*, *GABRA1*, *GABRA4* and *GABRB1*, were markedly associated with ion transport (P=6.05×10^−7^); DEGs such as *KCNJ5*, *KCND3*, *KCNJ6* and *KCNT2* were relevant to metal ion transport (P=3.87×10^−6^) and potassium ion transport (P=7.01×10^−5^); DEGs such as *DRD2*, *POU1F1* and *GHRHR* were distinctly associated with the positive regulation of multicellular organism growth (P=2.47×10^−4^), pituitary gland development (P=5.70×10^−4^), adenohypophysis development (P=8.52×10^−4^), diencephalon development (P=1.24×10^−3^) and endocrine system development (P=6.09×10^−3^); and DEGs such as *NOTCH2*, *ERBB4* and *POU1F1* were involved in cell fate commitment (P=3.22×10^−2^) and the regulation of cell proliferation (P=4.55×10^−2^) ([Table II](#tII-ol-0-0-3904){ref-type="table"}).

### According to the KEGG pathway enrichment analysis, the upregulated DEGs were mainly enriched in 10 pathways

For example, *CDC20*, *CCNB1*, *CCNB2*, *BUB1*, *CDKN1A* and *MCM3* were enriched in the pathway of the cell cycle (P=5.01×10^−7^); *CDC20*, *CCNB1*, *CCNB2*, *BUB1* and *PLK1* were distinctly enriched in the pathway of oocyte meiosis (P=1.058×10^−3^); *CCNB1*, *CCNB2*, *CCNA2*, *BUB1* and *PLK1* were significantly enriched in the pathway of progesterone-mediated oocyte maturation (P=1.150×10^−3^); and *CDKN1A*, *CCNB1*, *CCNB2* and *CASP8* were markedly enriched in the p53 signaling pathway (P=3.4841×10^−2^) ([Table III](#tIII-ol-0-0-3904){ref-type="table"}). Meanwhile, the downregulated DEGs were mainly enriched in 7 pathways. *GH1*, *GABRA1*, *GABRA4* and *GABRB1* were enriched in the pathway of neuroactive ligand-receptor interaction (P=4.35×10^−4^); *MAOB*, *ALDH2* and *ALDH1A7* were mainly enriched in the pathways of histidine metabolism (P=1.2476×10^−2^) and tryptophan metabolism (P=3.7487×10^−2^); *ATP2B4*, *ERBB4* and *PLCG2* were enriched in the calcium signaling pathway (P=3.9919×10^−2^); and *GSTA4*, *MGST1*, *GSTM7* were significantly enriched in the pathways of drug metabolism (P=1.4397×10^−2^) and glutathione metabolism (P=4.9294×10^−2^) ([Table III](#tIII-ol-0-0-3904){ref-type="table"}).

### Analysis of PPI network

The PPI networks constructed with the up- and downregulated DEGs consisted of 1,044 and 69 PPI pairs, respectively. In the former, *PTTG1*, along with *CCNB1*, *CCNA2*, *SPC25*, *CENPF*, *NUSAP1*, *CDC20*, *TOP2A* and *BUB1*, were observed to interact with each other ([Fig. 1](#f1-ol-0-0-3904){ref-type="fig"}). Within the PPI network built with downregulated DEGs, *GABRA1*, *GABRA4*, *GABRB1* and *GABRB1* were observed to interact with each other; *GSTA3*, *GSTA4*, *GSTM7* and *MGST1* were also found to interact with each other, and *POU1F1* was observed to interact with *POMC* ([Fig. 2](#f2-ol-0-0-3904){ref-type="fig"}). The connection degrees of the top 15% highly-connected upregulated DEGs were each \>30, and those of *CDK1*, *CCNB1*, *CCNA2* and *BUB1* were 51, 47, 46 and 44, respectively ([Table IV](#tIV-ol-0-0-3904){ref-type="table"}). The top 20% highly-connected downregulated DEGs all had connection degrees of at least 3, and the degrees of *POMC*, *GSTA4*, *POU1F1*, *ERBB4*, *KCND3* and *NOTCH2* were 6, 5, 4, 4, 3 and 3, respectively ([Table IV](#tIV-ol-0-0-3904){ref-type="table"}).

Discussion
==========

In the present study, 391 DEGs were identified to be significantly upregulated and 238 were significantly downregulated in the pituitary adenomas samples. According to the constructed PPI network with the upregulated DEGs, *PTTG1* interacted with other DEGs with higher connection degrees, such as *CCNB1*, *CCNA2*, *SPC25*, *CENPF*, *NUSAP1*, *CDC20*, *TOP2A* and *BUB1*.

*PTTG1*, a tumorigenic gene *in vivo* ([@b23-ol-0-0-3904]), is abundantly expressed in pituitary tumors ([@b24-ol-0-0-3904]). As a securin protein, *PTTG1* is correlated with the mitotic checkpoint that prevents abnormal chromosome segregation ([@b25-ol-0-0-3904]), and peaks at the G~2~/M phase ([@b26-ol-0-0-3904]). The overexpression of *PTTG1* results in cell transformation and induces aneuploidy ([@b27-ol-0-0-3904]), and this exists in \>90% of pituitary tumors ([@b28-ol-0-0-3904]). *PTTG1*, together with *CCNB1*, *CCNA2*, *BUB1*, *SPC25*, *CENPF*, *NUSAP1*, *TOP2A* and *CDC20*, were all found to be enriched in GO terms associated with the cell cycle or cell division, which are indispensable for tumor growth. It has been reported that *CDC20* is involved in the degradation of *PTTG1*-encoding products ([@b29-ol-0-0-3904]). Meanwhile, previous studies have also reported the abnormal expression of *CCNB1* ([@b30-ol-0-0-3904]), *CCNA2* ([@b31-ol-0-0-3904]), and *BUB1* ([@b32-ol-0-0-3904]) in pituitary adenomas. Furthermore, *CCNB1* was enriched in the p53 signaling pathway. *PTTG1*-encoding protein can cooperate with p53 to take part in cell apoptosis and DNA damage/repair ([@b33-ol-0-0-3904],[@b34-ol-0-0-3904]). Altered p53 expression has been reported in pituitary carcinomas ([@b35-ol-0-0-3904]). Also, *PTTG1* can activate β-fibroblast growth factor, cyclin D3 and c-myc to promote cell proliferation ([@b36-ol-0-0-3904],[@b37-ol-0-0-3904]). Therefore, *PTTG1* may play a crucial role in the occurrence of pituitary adenomas via interaction with *CCNB1*, *CCNA2*, *CENPF*, *NUSAP1*, *CDC20*, *TOP2A*, *BUB1* and p53.

Within the PPI network constructed with downregulated DEGs, *GABRA1*, *GABRA4* and *GABRB1* had higher degrees of connection to other genes. These genes were enriched in the pathway of neuroactive ligand-receptor interaction. *GABRA1*, *GABRA4* and *GABRB1* encode γ-aminobutyric acid (GABA) receptors. GABA is the major inhibitory neurotransmitter in the mammalian brain and may act as a paracrine or autocrine regulating factor in the human pituitary gland and human pituitary growth hormone adenomas ([@b38-ol-0-0-3904]). It has been reported that GABA has a specific effect on the electrical activity of a tumoral line of rat pituitary cells, and that it inhibits prolactin secretion directly at the pituitary level ([@b39-ol-0-0-3904]). Additionally, *POU1F1* was also observed to have a higher connection degree in the PPI network. This gene encoding a member of the POU family of transcription factors ([@b40-ol-0-0-3904]), was correlated with the development of the pituitary gland, adenohypophysis and endocrine system. In humans, *POU1F1* mutation has been shown to be associated with combined pituitary hormone deficiency ([@b41-ol-0-0-3904]). *POU1F1* is also implicated in cell growth and prevents cell apoptosis ([@b42-ol-0-0-3904]). In the present study, it was observed to interact with *POMC*, which encodes a polypeptide hormone precursor. The encoded polypeptide hormone precursor is synthesized mainly in corticotrophin cells of the anterior pituitary ([@b43-ol-0-0-3904]). A previous study has shown that in silent pituitary adenomas, *POMC* mRNA has a diffuse low level or is absent ([@b44-ol-0-0-3904]). Thus, *GABRA1*, *GABRA4*, *GABRB1*, *POU1F1* and *POMC* may also have critical roles in pituitary adenoma occurrence via close interaction.

In conclusion, upregulated DEGs, such as those associated with the cell cycle or cell division (e.g., *CCNB1*, *CCNA2*, *BUB1*, *CENPF*, *NUSAP1*, *CDC20*, *TOP2A* and particularly *PTTG1*) and downregulated DEGs, such as those relevant to neuroactive ligand-receptor interaction (e.g., *GABRA1*, *GABRA4* and *GABRB1*), as well as those correlated with the development of the pituitary gland, adenohypophysis and endocrine system (e.g., *POU1F1*) may have essential roles in the pathogenesis of pituitary adenomas. The present study provides novel information for the clinical diagnosis of this disease.
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###### 

Top two enriched GO biological process term clusters with the highest enrichment score for the upregulated differentially-expressed genes.

  Enrichment score   Term         Description                                                                 Count   P-value          Genes
  ------------------ ------------ --------------------------------------------------------------------------- ------- ---------------- ------------------------------------------------------------------------------
  7.432              GO:0007049   Cell cycle                                                                  31        1.08×10^−12^   *SPC25, CCNA2, CENPF, NUSAP1, CDC20, NDC80, CCNB1, PTTG1, CCNB2, BUB1B*...
                     GO:0022403   Cell cycle phase                                                            23        1.10×10^−12^   *NUSAP1, CENPF, NDC80, CDC20, CCNB1, PTTG1, SPC25, CDKN1A, PLK1, BUB1B*...
                     GO:0022402   Cell cycle process                                                          27        3.26×10^−12^   *PTTG1, SPC25, CDKN2C, CENPF, NUSAP1, CDC20, NDC80, CCNB1, CDKN1C, BUB1B*...
                     GO:0000279   M phase                                                                     19        3.09×10^−11^   *NUSAP1, CENPF, NDC80, CDC20, PTTG1, CCNB1, SPC25, PLK1, BUB1B, SKA3*...
                     GO:0051301   Cell division                                                               14      1.25×10^−7^      *NUSAP1, CDC20, PTTG1, CCNB1, SPC25, CCNB2, PLK1, BUB1B, TOP2A, CCNA2*...
                     GO:0000087   M phase of mitotic cell cycle                                               12      2.16×10^−7^      *CCNB1, SPC25, PLK1, NUF2, NUSAP1, BUB1B, SKA3, CENPF, CDC20, PTTG1*...
                     GO:0000278   Mitotic cell cycle                                                          16      5.40×10^−7^      *NUSAP1, CENPF, NDC80, CDC20, PTTG1, CCNB1, SPC25, CDKN1A, CDKN2C, BUB1B*...
                     GO:0000280   Nuclear division                                                            10      1.09×10^−5^      *CCNB1, SPC25, KIF11, PLK1, NUF2, NUSAP1, BUB1B, SKA3, CDC20, PTTG1*
                     GO:0007067   Mitosis                                                                     10      1.09×10^−5^      *CCNB1, SPC25, KIF11, PLK1, NUF2, NUSAP1, BUB1B, SKA3, CDC20, PTTG1*
                     GO:0048285   Organelle fission                                                           10      1.74×10^−5^      *CCNB1, SPC25, KIF11, PLK1, NUF2, NUSAP1, BUB1B, SKA3, CDC20, PTTG1*
                     GO:0051439   Regulation of ubiquitin-protein ligase activity during mitotic cell cycle     4     4.86×10^−2^      *CCNB1, PLK1, BUB1B, CDC20*
  5.335              GO:0000279   M phase                                                                     19        3.09×10^−11^   *NUSAP1, CENPF, NDC80, CDC20, PTTG1, CCNB1, SPC25, PLK1, BUB1B, SKA3*...
                     GO:0051327   M phase of meiotic cell cycle                                                 7     2.32×10^−4^      *ADCY3, KIF2C, MKI67, PLK1, SGOL2, PTTG1, RAD51*
                     GO:0007126   Meiosis                                                                       7     2.32×10^−4^      *ADCY3, KIF2C, MKI67, PLK1, SGOL2, PTTG1, RAD51*
                     GO:0051321   Meiotic cell cycle                                                            7     2.76×10^−4^      *ADCY3, KIF2C, MKI67, PLK1, SGOL2, PTTG1, RAD51*

GO, gene ontology.

###### 

Top two enriched GO biological process term clusters with the highest enrichment score for the downregulated differentially-expressed genes.

  Enrichment score   Term         Description                                                           Count   P-value       Genes
  ------------------ ------------ --------------------------------------------------------------------- ------- ------------- --------------------------------------------------------------------------------------
  4.727              GO:0006811   Ion transport                                                         16      6.05×10^−7^   *KCND3, GABRA1, GABRA4, GABRB2, GABRB1, CACNG6, ATP2B4, KCNT2, KCNH7, CACNA1A*......
                     GO:0030001   Metal ion transport                                                   12      3.87×10^−6^   *KCNJ5, KCND3, KCNJ6, ATP2B4, CACNG6, KCNH7, KCNH8, SCNN1G, KCNJ3, CACNA1A*......
                     GO:0006812   Cation transport                                                      12      2.54×10^−5^   *KCNJ5, KCND3, KCNJ6, ATP2B4, CACNG6, KCNH7, KCNH8, SCNN1G, KCNJ3, CACNA1A*......
                     GO:0006813   Potassium ion transport                                                 7     7.01×10^−5^   *KCNJ5, KCND3, KCNJ6, KCNT2, KCNH7, KCNH8, KCNJ3*
                     GO:0015672   Monovalent inorganic cation transport                                   8     5.52×10^−4^   *KCNJ5, KCND3, KCNJ6, KCNT2, KCNH7, KCNH8, SCNN1G, KCNJ3*
  2.321              GO:0040018   Positive regulation of multicellular organism growth                    4     2.47×10^−4^   *GH1, DRD2, POU1F1, GHRHR*
                     GO:0021983   Pituitary gland development                                             4     5.70×10^−4^   *DRD2, POU1F1, GHRHR, TBX19*
                     GO:0021984   Adenohypophysis development                                             3     8.52×10^−4^   *DRD2, POU1F1, GHRHR*
                     GO:0021536   Diencephalon development                                                4     1.24×10^−3^   *DRD2, POU1F1, GHRHR, TBX19*
                     GO:0043567   Regulation of insulin-like growth factor receptor signaling pathway     3     1.82×10^−3^   *GH1, POU1F1, GHRHR*
                     GO:0040014   Regulation of multicellular organism growth                             4     4.82×10^−3^   *GH1, DRD2, POU1F1, GHRHR*
                     GO:0035270   Endocrine system development                                            4     6.09×10^−3^   *DRD2, POU1F1, GHRHR, TBX19*
                     GO:0030900   Forebrain development                                                   5     9.58×10^−3^   *ERBB4, DRD2, POU1F1, GHRHR, TBX19*
                     GO:0045927   Positive regulation of growth                                           4     9.75×10^−3^   *GH1, DRD2, POU1F1, GHRHR*
                     GO:0048732   Gland development                                                       5     1.75×10^−2^   *ERBB4, DRD2, POU1F1, GHRHR, TBX19*
                     GO:0045165   Cell fate commitment                                                    4     3.22×10^−2^   *NOTCH2, ERBB4, POU1F1, TBX19*
                     GO:0051240   Positive regulation of multicellular organismal process                 5     3.49×10^−2^   *GH1, ERBB4, DRD2, POU1F1, GHRHR*
                     GO:0042127   Regulation of cell proliferation                                        8     4.55×10^−2^   *NOTCH2, ERBB4, DRD2, NR3C2, CDK6, POU1F1, GHRHR, TBX19*

GO, gene ontology.

###### 

Results of pathway enrichment analysis of the up- and downregulated differentially-expressed genes.

  Category        Term       Description                               Count   P-value       Genes
  --------------- ---------- ----------------------------------------- ------- ------------- -------------------------------------------------------------------------------
  Upregulated     rno04110   Cell cycle                                14      5.01×10^−7^   *CDC20, MCM3, CDKN1C, CCNB1, CDKN1A, CCNB2, CDKN2C, BUB1, BUB1B, CCNA2*......
                  rno04114   Oocyte meiosis                              9     1.06×10^−3^   *CCNB1, ADCY3, AR, CCNB2, MAPK12, PLK1, BUB1, CDC20, PTTG1*
                  rno00601   Glycosphingolipid biosynthesis              5     1.10×10^−3^   *B4GALT1, B3GALT2, B3GALT5, FUT4, B4GALT4*
                  rno04914   Progesterone-mediated oocyte maturation     8     1.15×10^−3^   *CCNB1, ADCY3, CCNB2, KRAS, MAPK12, PLK1, BUB1, CCNA2*
                  rno04062   Chemokine signaling pathway                 9     1.46×10^−2^   *ADCY3, KRAS, LYN, ARRB1, PREX1, GRK5, PRKCD, CCL6, SHC4*
                  rno00330   Arginine and proline metabolism             5     1.70×10^−2^   *ARG1, GOT1, NOS1, ASS1, GAMT*
                  rno05219   Bladder cancer                              4     2.94×10^−2^   *CDKN1A, KRAS, PGF, VEGFA*
                  rno04115   p53 signaling pathway                       5     3.48×10^−2^   *CCNB1, CDKN1A, CCNB2, CASP8, IGFBP3*
                  rno04610   Complement and coagulation cascades         5     4.19×10^−2^   *C1QA, A2M, C1S, C1QC, F2R*
                  rno00510   N-glycan biosynthesis                       4     4.89×10^−2^   *B4GALT1, MAN2A1, ALG5, MAN1A1*
  Downregulated   rno04080   Neuroactive ligand-receptor interaction     9     4.35×10^−4^   *GH1, GABRA1, GABRA4, GABRB2, DRD2, GABRB1, TSHB, LHB, GHRHR*
                  rno00410   β-alanine metabolism                        3     1.05×10^−2^   *ALDH2, ALDH1A7, DPYD*
                  rno00340   Histidine metabolism                        3     1.25×10^−2^   *MAOB, ALDH2, ALDH1A7*
                  rno00982   Drug metabolism                             4     1.44×10^−2^   *GSTA4, MAOB, MGST1, GSTM7*
                  rno00380   Tryptophan metabolism                       3     3.75×10^−2^   *MAOB, ALDH2, ALDH1A7*
                  rno04020   Calcium signaling pathway                   5     3.99×10^−2^   *ATP2B4, ERBB4, PLCG2, PLCB1, CACNA1A*
                  rno00480   Glutathione metabolism                      3     4.93×10^−2^   *GSTA4, MGST1, GSTM7*

###### 

Upregulated DEGs with connection degrees of \>30 and the downregulated DEGs with connection degrees of at least 3 in the protein-protein interaction networks.

  Category             Degree
  -------------------- --------
  Upregulated DEGs     
    *CDK1*             51
    *CCNB1*            47
    *CCNA2*            46
    *BUB1*             44
    *ECT2*             43
    *TPX2*             42
    *NDC80*            42
    *PRC1*             42
    *NUSAP1*           41
    *TOP2A*            41
    *CCNB2*            41
    *PBK*              41
    *RACGAP1*          41
    *TTK*              41
    *PIK1*             40
    *SPC25*            40
    *BUB1B*            40
    *CENPF*            40
    *CDKN3*            39
    *NUF2*             38
    *CDC20*            38
    *KIF11*            38
    *DLGAP5*           38
    *SGOL2*            37
    *DTL*              36
    *KIF20A*           36
    *CDCA2*            36
    *KIF20B*           35
    *ESCO2*            35
    *RAD51*            34
    *ARHGAP11A*        34
    *CKAP2*            33
    *HMMR*             33
    *KIF2C*            32
    *DEPDC1*           32
  Downregulated DEGs   
    *POMC*               6
    *GSTA4*              5
    *GSTA1*              5
    *POU1F1*             4
    *ERBB4*              4
    *GABRA1*             3
    *MGST1*              3
    *GABRA4*             3
    *GSTM7*              3
    *ALDH2*              3
    *GH1*                3
    *NR4A2*              3
    *MAOB*               3
    *KCND3*              3
    *NOTCH2*             3
    *GABRB1*             3

DEGs, differentially-expressed genes.
